Conclusions
1 evidence topic · 19 sources
Summary
Huntington's disease (HD) is an autosomal dominant, progressive disorder of motor, cognitive, and psychiatric manifestations, with a median survival time after onset of 15 to 18 years. The sponsor states that approximately 75,000 people have HD in the U.S., EU, and UK, with approximately 40,000 symptomatic patients in the U.S. The Huntington's Disease Society of America states that there is currently no cure or treatment that can halt, slow, or reverse progression of the disease, and the sponsor states that there are currently no approved therapies to delay the onset or slow the progression of HD.
Ifezuntirgene inilparvovec (AMT-130) is given as a single administration by MRI-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum (caudate and putamen). Its efficacy evidence consists of pooled data from the U.S. phase I/II and European phase Ib/II studies compared with a propensity score-matched external control from the Enroll-HD natural history data set. In the three-year analysis (data cutoff June 30, 2025), 29 participants had been treated (17 high dose, 12 low dose), and 12 per dose group had 36 months of follow-up. In the high-dose group, mean change in cUHDRS from baseline was -0.38 compared with -1.52 for the external control, a 75% slowing of disease progression (p=0.003) that met the primary endpoint, and TFC showed a 60% slowing (p=0.033); in the low-dose group, mean change in cUHDRS was -1.65 compared with -1.72 (p=0.871). At 48 months, against an updated external control, the 12 high-dose participants showed a 44% slowing on cUHDRS that did not reach statistical significance (p=0.144) and a 61% slowing on TFC (nominal p=0.008). The most common adverse events were related to the administration procedure, and all resolved. Five high dose participants (17%) experienced a treatment-related serious adverse event related to central nervous system inflammation, all of which fully resolved; in the four-year presentation's cumulative safety table, 20 (39.2%) treated participants had any serious adverse event and 5 (9.80%) a drug-related serious adverse event. One low-dose participant died by suicide approximately five years after treatment, which the study investigator assessed as unrelated to treatment.
The BLA was submitted under the Accelerated Approval pathway and has Priority Review with a PDUFA target action date of May 1, 2027; the FDA stated that it is tentatively planning to discuss the application at an Advisory Committee meeting. The Form 10-Q states that the BLA was submitted in August 2026 and accepted in October 2026, and that acceptance was announced on November 2, 2026. The BLA is supported by 36-month data from 12 high-dose participants compared with a propensity score-matched external control. The FDA's position on this evidence changed over time: at a Type B meeting held in late November, as the company reported in 2024, it agreed that the phase I/II data compared with a natural history external control may serve as the primary basis for a BLA under the Accelerated Approval pathway; after a pre-BLA meeting held on October 29, 2025, it conveyed that the data “are currently unlikely to provide the primary evidence” to support a BLA submission; after a Type A meeting held on January 30, 2026, it stated that it cannot agree that the data are sufficient and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study; and after a subsequent Type B meeting, it communicated that the 3-year analysis would be acceptable as the primary basis of a BLA for accelerated approval. The confirmatory study is designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 participants randomized 2:1, with TFC as the primary endpoint at 36 months, and patient screening is planned to begin in the U.S. by the end of 2026.
ICER's model analysis plan uses a placeholder price of $2,600,000, the midpoint of a $1,700,000 lower value (Leerink Partners) and a $3,500,000 upper value (IPD analytics), with an administration price of $24,138.83. A published cost-effectiveness analysis assumed the cost of AMT-130 to be the list price of Zolgensma less a 15% payer discount ($1,806,250); compared with standard of care, AMT-130 increased costs by $1.49 million and QALYs by 5.23, an incremental cost-effectiveness ratio of $285,703 per QALY gained. ICER estimates 25,811 eligible patients in the US from a prevalence of approximately 40,000 people and the approximately 62.7% in SF stage 1 or 2, and assumes that 20% initiate treatment in each of five years (5,162 patients per year).
The limitations summaries name the following uncertainties. The analyses rely on external historical controls, which the Form 10-K states may not be accepted as a basis for regulatory approval, and one commentary noted that the evidence of efficacy “depends entirely on the ENROLL-HD controls being well-matched”. MRI data were not collected in Enroll-HD, so striatal volume could not be matched; most participants were in open-label arms, so a placebo effect is possible; 12 high-dose participants contributed 36-month data to the three-year analysis, 15 to the updated 36-month analysis, and 12 to the 48-month analysis; data missingness in the updated Enroll-HD matched controls reached 53% at 48 months; and several p-values are nominal. The results are reported in company press releases, presentations, and SEC filings. ICER's base case assumes that the treatment effect remains constant over the lifetime horizon, and the authors of the published cost-effectiveness analysis state that their model relied heavily on the assumption of sustained benefit beyond the data.